AU2018388549B2 - Compounds and compositions for treating fibrosis - Google Patents

Compounds and compositions for treating fibrosis Download PDF

Info

Publication number
AU2018388549B2
AU2018388549B2 AU2018388549A AU2018388549A AU2018388549B2 AU 2018388549 B2 AU2018388549 B2 AU 2018388549B2 AU 2018388549 A AU2018388549 A AU 2018388549A AU 2018388549 A AU2018388549 A AU 2018388549A AU 2018388549 B2 AU2018388549 B2 AU 2018388549B2
Authority
AU
Australia
Prior art keywords
group
mkp
compound
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018388549A
Other languages
English (en)
Other versions
AU2018388549A1 (en
Inventor
Karen S. Anderson
Anton BENNETT
Jonathan Ellman
Denton HOYER
Haya JAMALI
Elias Lolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2018388549A1 publication Critical patent/AU2018388549A1/en
Application granted granted Critical
Publication of AU2018388549B2 publication Critical patent/AU2018388549B2/en
Priority to AU2023204581A priority Critical patent/AU2023204581B2/en
Priority to AU2025234269A priority patent/AU2025234269A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AU2018388549A 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis Active AU2018388549B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023204581A AU2023204581B2 (en) 2017-12-18 2023-07-11 Compounds and compositions for treating fibrosis
AU2025234269A AU2025234269A1 (en) 2017-12-18 2025-09-22 Compounds and compositions for treating fibrosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607110P 2017-12-18 2017-12-18
US62/607,110 2017-12-18
PCT/US2018/066191 WO2019126141A1 (en) 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204581A Division AU2023204581B2 (en) 2017-12-18 2023-07-11 Compounds and compositions for treating fibrosis

Publications (2)

Publication Number Publication Date
AU2018388549A1 AU2018388549A1 (en) 2020-07-02
AU2018388549B2 true AU2018388549B2 (en) 2023-06-01

Family

ID=66993802

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018388549A Active AU2018388549B2 (en) 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis
AU2023204581A Active AU2023204581B2 (en) 2017-12-18 2023-07-11 Compounds and compositions for treating fibrosis
AU2025234269A Pending AU2025234269A1 (en) 2017-12-18 2025-09-22 Compounds and compositions for treating fibrosis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023204581A Active AU2023204581B2 (en) 2017-12-18 2023-07-11 Compounds and compositions for treating fibrosis
AU2025234269A Pending AU2025234269A1 (en) 2017-12-18 2025-09-22 Compounds and compositions for treating fibrosis

Country Status (9)

Country Link
US (3) US11504373B2 (https=)
EP (1) EP3732179B1 (https=)
JP (2) JP7317039B2 (https=)
KR (1) KR20200100726A (https=)
CN (2) CN116687934A (https=)
AU (3) AU2018388549B2 (https=)
CA (1) CA3085770A1 (https=)
MX (2) MX2020006398A (https=)
WO (1) WO2019126141A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018388549B2 (en) * 2017-12-18 2023-06-01 Yale University Compounds and compositions for treating fibrosis
US12570670B2 (en) * 2019-01-30 2026-03-10 Yale University Compounds, compositions, and methods for treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086859A1 (en) 2000-04-10 2004-05-06 Klaus Ducker Identification of a dual specificity phosphate: dusp-10
DE60125783T2 (de) * 2000-08-11 2007-10-18 Evotec Ag Verfahren zum nachweis von acetylase oder deacetylase-aktivität in einem immunoassay
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP2007518702A (ja) * 2003-11-25 2007-07-12 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体処置の効力についてのバイオマーカー
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2351571A4 (en) * 2008-10-09 2012-08-01 Lsip Llc PROTEINPHOSPHATASEHEMMER
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
AU2018388549B2 (en) * 2017-12-18 2023-06-01 Yale University Compounds and compositions for treating fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "MAP Kinase Phosphatase-5 (MKP-5) as a novel anti-fibrotic therapeutic target", OCR7100: NON-CONFIDENTIAL, 4 January 2017 (2017-01-04), pages 8, 16, 17, XP055620308, Retrieved from the Internet [retrieved on 20190415] *
TUIJA HÖMMÖ ET AL: "Regulation of Inflammatory Cytokine Production by MKP-5 in Macrophages", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 117, no. 2, 1 August 2015 (2015-08-01), pages 96 - 104 *

Also Published As

Publication number Publication date
KR20200100726A (ko) 2020-08-26
JP2021506975A (ja) 2021-02-22
JP2023145544A (ja) 2023-10-11
EP3732179B1 (en) 2024-05-01
EP3732179A1 (en) 2020-11-04
EP3732179A4 (en) 2022-01-19
US20240335445A1 (en) 2024-10-10
CN111670188A (zh) 2020-09-15
AU2023204581A1 (en) 2023-10-05
AU2023204581B2 (en) 2025-06-26
CN116687934A (zh) 2023-09-05
JP7317039B2 (ja) 2023-07-28
US20200390770A1 (en) 2020-12-17
MX2020006398A (es) 2020-09-07
CA3085770A1 (en) 2019-06-27
MX2023009895A (es) 2023-09-04
CN111670188B (zh) 2023-06-23
AU2025234269A1 (en) 2025-10-16
US20230181588A1 (en) 2023-06-15
WO2019126141A1 (en) 2019-06-27
JP7676477B2 (ja) 2025-05-14
US11504373B2 (en) 2022-11-22
AU2018388549A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
US20240335445A1 (en) Compounds and Compositions for Treating Fibrosis
Freitas et al. NF-κB-IKKβ pathway as a target for drug development: Realities, challenges and perspectives
Hu et al. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges
US9532984B2 (en) Therapeutic combination for cancer treatment
JP2003506388A (ja) 疼痛および不安症を処置または予防するための方法
EP1636183A1 (en) Pyrrole compounds and uses thereof
US10738061B2 (en) Inhibitors of RAD52 recombination protein and methods using same
WO2012009688A1 (en) Organic compounds
CA2813743C (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
JP2021167301A (ja) Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
KR20250040736A (ko) 암의 치료를 위한 kat6 억제제를 포함하는 투여 요법
CA2586987A1 (en) Methods and compositions for treating cellular proliferative diseases
Seifert et al. Inhibitors of Bacillus anthracis edema factor
AU2021236930A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
US12570670B2 (en) Compounds, compositions, and methods for treating fibrosis
HK40098110A (zh) 用於治疗纤维化的化合物和组合物
Supuran et al. Carbonic anhydrase inhibitors–part 70. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering agents derived from nicotinic acid and aromatic/heterocyclic sulfonamides
US20220152077A1 (en) Adenosine receptor agonists
US20090264383A1 (en) Inhibitor of Adenylyl Cyclase for Treating a Disorder of the Circadian Rhythm
JP2002338467A (ja) アデニル酸シクラーゼ５型阻害剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)